Challenges and opportunities for cheat therapy in the control of bacterial infections.


Journal

Natural product reports
ISSN: 1460-4752
Titre abrégé: Nat Prod Rep
Pays: England
ID NLM: 8502408

Informations de publication

Date de publication:
23 02 2022
Historique:
pubmed: 17 12 2021
medline: 7 4 2022
entrez: 16 12 2021
Statut: epublish

Résumé

Covering: 1999 to 2021Bacterial pathogens can be highly social, communicating and cooperating within multi-cellular groups to make us sick. The requirement for collective action in pathogens presents novel therapeutic avenues that seek to undermine cooperative behavior, what we call here 'cheat therapies'. We review two broad avenues of cheat therapy: first, the introduction of genetically engineered 'cheat' strains (bio-control cheats), and second the chemical induction of 'cheat' behavior in the infecting pathogens (chemical-control cheats). Both genetically engineered and chemically induced cheats can socially exploit the cooperative wildtype infection, reducing pathogen burden and the severity of disease. We review the costs and benefits of cheat therapies, highlighting advantages of evolutionary robustness and also the challenges of low to moderate efficacy, compared to conventional antibiotic treatments. We end with a summary of what we see as the most valuable next steps, focusing on adjuvant treatments and use as alternate therapies for mild, self-resolving infections - allowing the reservation of current and highly effective antibiotics for more critical patient needs.

Identifiants

pubmed: 34913456
doi: 10.1039/d1np00053e
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-334

Auteurs

James Gurney (J)

Center for Microbial Dynamics & Infection, Georgia Institute of Technology, Atlanta, 30332 GA, USA. jgurney7@gatech.edu.
School of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332 GA, USA.

Camille Simonet (C)

Institute of Evolutionary Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.

Kristofer Wollein Waldetoft (K)

Center for Microbial Dynamics & Infection, Georgia Institute of Technology, Atlanta, 30332 GA, USA. jgurney7@gatech.edu.
School of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332 GA, USA.
Torsby Hospital, Torsby, Sweden.

Sam P Brown (SP)

Center for Microbial Dynamics & Infection, Georgia Institute of Technology, Atlanta, 30332 GA, USA. jgurney7@gatech.edu.
School of Biological Sciences, Georgia Institute of Technology, Atlanta, 30332 GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH